PI3K Inhibition for Squamous Cell Head and Neck Carcinoma

被引：5
|
作者：
Desilets, Antoine [1 ,2 ]
Soulieres, Denis [1 ]
机构：
[1] Ctr Hosp Univ Montreal CHUM, Pavillon C,1000 Rue St Denis, Montreal, PQ H2X 0C1, Canada
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER JOURNAL | 2022年 / 28卷 / 05期
关键词：
Head and neck squamous cell carcinoma; PI3K inhibitors; targeted therapy; PHOSPHOINOSITIDE 3-KINASE INHIBITOR; I DOSE-ESCALATION; BUPARLISIB BKM120; PACLITAXEL; RECURRENT; CHEMOTHERAPY; COMBINATION; EXPRESSION; RECEPTOR; NIVOLUMAB;
D O I：
10.1097/PPO.0000000000000618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in most head and neck squamous cell carcinomas, making it a prized target for targeted therapy development. Multiple PI3K inhibitors have been studied in early phase trials, with unfavorable risk-benefit ratios in molecularly unselected patient populations. Buparlisib, a potent pan-class I PI3K inhibitor, shows promising efficacy in combination with paclitaxel for advanced head and neck squamous cell carcinoma. Results of the phase III BURAN trial are awaited.
引用
收藏
页码：369 / 376
页数：8
相关论文
共 50 条
  • [1] Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: A systematic review
    Alves, L. B.
    Moura, A. C.
    dos Santos, J. Amorim
    Borges, G. A.
    Guerra, E. N. S.
    TOXICOLOGY IN VITRO, 2023, 88
  • [2] Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma
    Cai, Yi
    Dodhia, Sonam
    Su, Gloria H.
    ONCOTARGET, 2017, 8 (13) : 22203 - 22217
  • [3] Evaluation of co-inhibition of ErbB family kinases and PI3K for HPV-negative head and neck squamous cell carcinoma
    Geng, Xinyan
    Azarbarzin, Shirin
    Yang, Zejia
    Lapidus, Rena G.
    Fan, Xiaoxuan
    Teng, Yong
    Mehra, Ranee
    Cullen, Kevin J.
    Dan, Hancai
    ONCOLOGY REPORTS, 2025, 53 (03)
  • [4] PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma
    Wang, Libo
    Chen, Kejun
    Weng, Siyuan
    Xu, Hui
    Ren, Yuqing
    Cheng, Quan
    Luo, Peng
    Zhang, Jian
    Liu, Zaoqu
    Han, Xinwei
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [5] CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3Kα Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma
    Remer, Eric
    Badarni, Mai
    Hikri, Elad
    Dayan, Avraham
    Levi, Lirit
    Popovtzer, Aron
    Iraqi, Muhammed
    Porgador, Angel
    Joshua, Ben-Zion
    Bachar, Gideon
    Elkabets, Moshe
    Scaltriti, Maurizio
    Mizrachi, Aviram
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 12
  • [6] Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition
    Ruicci, Kara M.
    Plantinga, Paul
    Pinto, Nicole
    Khan, Mohammed I.
    Stecho, William
    Dhaliwal, Sandeep S.
    Yoo, John
    Fung, Kevin
    MacNeil, Danielle
    Mymryk, Joe S.
    Barrett, John W.
    Howlett, Christopher J.
    Nichols, Anthony C.
    MOLECULAR ONCOLOGY, 2019, 13 (10) : 2160 - 2177
  • [7] Overexpressed HGF promotes metastasis of squamous cell carcinoma of the head and neck through the PI3K/Akt and JNK signaling pathways
    Guo, Nan
    Liang, Jiwang
    Gao, Xin
    Yang, Xiao
    Fan, Xinlong
    Zhao, Yuejiao
    FUTURE ONCOLOGY, 2021, 17 (33) : 4527 - 4543
  • [8] Immunotherapy for squamous cell carcinoma of the head and neck
    Yokota, Tomoya
    Homma, Akihiro
    Kiyota, Naomi
    Tahara, Makoto
    Hanai, Nobuhiro
    Asakage, Takahiro
    Matsuura, Kazuto
    Ogawa, Takenori
    Saito, Yuki
    Sano, Daisuke
    Kodaira, Takeshi
    Motegi, Atsushi
    Yasuda, Koichi
    Takahashi, Shunji
    Tanaka, Kaoru
    Onoe, Takuma
    Okano, Susumu
    Imamura, Yoshinori
    Ariizumi, Yosuke
    Hayashi, Ryuichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (10) : 1089 - 1096
  • [9] PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy
    Chuang, Fu-Cheng
    Wang, Chih-Chun
    Chen, Jian-Han
    Hwang, Tzer-Zen
    Yeh, Shyh-An
    Su, Yu-Chieh
    PLOS ONE, 2021, 16 (01):
  • [10] HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines
    Foki, Elisabeth
    Stanisz, Isabella
    Kadletz, Lorenz
    Kotowski, Ulana
    Seemann, Rudolf
    Schmid, Rainer
    Heiduschka, Gregor
    WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (1-2) : 26 - 31
12345